Altimmune Stock Surges, Kerrisdale Remains Short: What You Need To Know
Portfolio Pulse from Adam Eckert
Altimmune Inc (NASDAQ:ALT) shares surged despite no company-specific news, continuing a trend of volatility following positive trial results for pemvidutide and a short position announcement by Kerrisdale Capital. Kerrisdale remains short, citing competition concerns in the GLP-1 space. Altimmune is expected to report a Q4 loss of 43 cents per share with revenue around $2,140. The stock's long-term forecast suggests a potential price of $36.34 by 2030 based on past performance.
February 26, 2024 | 3:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune Inc's stock surged despite Kerrisdale Capital's short position, with expectations of a Q4 loss. Long-term forecasts suggest a potential rise to $36.34 by 2030.
The surge in Altimmune's stock price despite Kerrisdale Capital's short position indicates investor confidence, possibly due to positive trial results for pemvidutide. The expected Q4 loss is already priced in, and the long-term forecast based on past performance suggests optimism for future growth.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100